Saniona AB (publ) (OM: SANION)
Health Care · Biotechnology · DK
Skr9.57
-0.26% today · -21.8% 1Y
Saniona AB (publ) (OM: SANION) operates in the Biotechnology industry within the Health Care sector. The company is valued at $132.11M and employs 44 people.
Over the last twelve months the share price has lost 21.8%, trading between 8.53 and 28.30.
Tweenvest scores Saniona AB (publ) across four factors: quality 75/100, value 40/100, growth 100/100. Its strongest factor is growth.
SANION price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $132.11M
- Revenue (TTM)
- $43.80M
- P/E
- 7.33
- EPS
- 1.31
- Dividend yield
- —
- Beta (5Y)
- 1.16
- 52-week high
- Skr28.30
- 52-week low
- Skr8.53
- Avg volume (3M)
- —
- Shares outstanding
- 138.03M
- Employees
- 44
- Next earnings
- —
About Saniona AB (publ)
Saniona AB (publ), founded in 2011 and based in Glostrup, Denmark, is a biopharmaceutical company focused on rare diseases. It specializes in discovering, developing, and commercializing treatments specifically targeting central nervous system disorders. The company's pipeline features Tesofensine, a monoamine reuptake inhibitor, and Tesomet, a fixed-dose combination of tesofensine and metoprolol, which has advanced through Phase 2 clinical trials for Prader-Willi Syndrome and hypothalamic obesity. Additionally, Saniona is progressing SAN711, currently in Phase 1 for rare neuropathic conditions, and SAN903, an early-stage candidate in preclinical development for rare inflammatory, fibrotic, and hematological ailments. Saniona also engages in various strategic collaborations, including research and partnership agreements with Boehringer Ingelheim International GmbH, a licensing deal with Productos Medix, S.A. de C.V., and both research services and collaboration agreements with Cephagenix ApS.
- ISIN
- SE0005794617
- Founded
- 2011
- Listed since
- Apr 22, 2014
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Armata Pharmaceuticals, Inc.NYSEAM: ARMP | $134.97M | $3.58 | -1.38% |
| Innate Pharma S.A.ENXTPA: IPH | $134.19M | €1.28 | -1.54% |
| NIBEC Co., Ltd.KOSDAQ: A138610 | $132.33M | ₩15,650.00 | -2.07% |
| StemCyte International, Ltd.TWSE: 4178 | $132.32M | NT$19.60 | +8.89% |
| Orthocell LimitedASX: OCC | $131.16M | AU$0.69 | -9.21% |
| Tenaya Therapeutics, Inc.NasdaqCM: TNYA | $130.12M | $0.57 | -2.55% |
| NKGen Biotech Korea Co., Ltd.KOSDAQ: A182400 | $128.86M | ₩— | — |
| Spruce Biosciences, Inc.NasdaqCM: SPRB | $126.60M | $42.87 | -2.68% |
Figures last refreshed Oct 11, 2026.